Identification and management of drug-drug interactions between
hydroxychloroquine and long-term treatments in COVID-19 patients
Due to COVID-19 global pandemic, treatment with HCQ, although
controversial, has been widely prescribed. The aim of our study was to
identify drug-drug interactions (DDI) between HCQ and long-term
treatments of COVID-19 patients, focusing on drugs which can cause or
promote QT prolongation. From March 13 to April 14 2020, 61 patients
were treated with HCQ in our hospital. More than a half of patients
(62%) had at least one DDI between HCQ and their long-term treatments.
A large number of drug classes were involved, included contraindicated
drugs The mean of co-medication contraindicated or not recommended with
HCQ per patient was 1.9 CI95% [1.48 to 2.27]. All contraindicated
drugs were discontinued at the beginning of HCQ treatment due to
multidisciplinary meetings involving physicians and clinical
pharmacists. To our knowledge this is the first study about DDI between
HCQ and long-term treatments of COVID-19 patients.